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ABSTRACT 
Temporal Changes in the Spatial Distribution of Venture Capital Investment to Biotechnology 
Companies Within the United States 
 
by 
 
Rocky Graziano Bilotta 
 
The objective of this research is to investigate temporal changes in the spatial distribution of 
venture capital investments to biotechnology companies within the United States. Data included 
venture capital to biotech investments from 1995 to 2005. Venture capital and biotech data from 
the Money Tree Report, were gathered, analyzed, and mapped to show if a spatial relationship 
exists. The research examined venture capital investments at both the individual and the 
aggregated levels. At the individual level, the research examined whether the amount of 
investments a biotech company receives are influenced by physical distance to its closest 
investor, number of venture capitalists, time, region, sequence, company size, stage of 
development, etc. The research also included an aggregated study examining the changing 
patterns of investments in metropolitan areas. This research further enhances knowledge on the 
spatial distribution of investments. 
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CHAPTER 1 
INTRODUCTION 
Much work has been completed on the significance of the venture capital industry and the 
biotechnology industry. Far less has been accomplished in reference to the relationship of the 
locations of venture capitalist and biotechnology, considering biotech’s dependency on venture 
capital funds.  
In the biotechnology industry, there are thousands of companies employing more than 
150,000 people in the United States, making them the world leader in biotechnology (Sainsbury, 
1999). Biotechnology firms, and the venture capital firms that fund them, are highly clustered in 
certain key U.S. regions. According to Powell, Koput, Bowie, and Smith-Doerr (2002), more 
than half of the biotech firms in the United States received locally-based venture funding from 
1988 - 1999. Most corporations that received non-local funding have a tendency to be older, 
larger, and have research projects further along the commercialization process. The case is 
similar for venture capital firms. As these firms grow older and larger, they invest more in non-
local firms (Powell et al., 2002). 
Venture capital investment in the United States has resembled a roller coaster pattern 
beginning in the 1970s, reaching its peak during the Internet bubble in 1999 and 2000. Majority 
of the venture capital investments during the bubble period funded companies in the Internet and 
telecommunications industries and had little influence on the biotechnology industry. After the 
bubble period subsided, the Internet and telecommunication industries suffered a rapid decline in 
investments, while funding for biomedical ventures has continued to increase (Powell, White, 
Koput, & Owen-Smith, 2003). 
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There are several factors that come into play when a venture capital company is deciding 
on investing into a particular biotechnology company. In the past, research has shown that 
significant considerations for venture capitalist are: location of the industry, age of the industry, 
size of the industry, success of the industry, etc. (Powell et al,. 2002). Other factors also include 
the age, size, and experience of the venture capital company. According to these factors, a 
venture capital company may choose to invest in either a local or a non-local biotech company. 
Overtime, there has been an increase emergence of new biotech companies in newer regions (e.g. 
Research Triangle, NC) and an increase emergence of new venture capital companies. 
Currently, there are relatively few publications that explain or refer to the spatial 
relationship between venture capitalists and biotechnology companies. Thus, the purpose of this 
paper is to provide insight on the unique relationship between the locations of venture capitalists 
and the locations of their funded biotechnology companies. More importantly, this research will 
attempt to explain what variables influence the amount of capital a biotechnology company 
receives from its venture capitalist.  
 The research methodology for this study consists of three parts. The initial step includes 
the means of gathering and collecting the data. Data included only records of venture capital 
firms investing in biotechnology companies from 1995 to 2005 within the United States. All data 
were collected by accessing Pricewaterhouse Coopers’ the Money Tree Report website. The 
Money Tree Report was chosen because of its data, its use of updated information from reliable 
sources, and ease of accessibility. The second step consisted of the use of Geographic 
Information Systems (GIS) to display the locations of venture capital firms and biotechnology 
companies. Maps were also created using GIS to provide visual aids of the geographic locations 
of venture capitalists and biotechnology companies, their geographic regions, and the percent of 
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reallocation from 1995 to 2005 by region. The final step included the use of Statistical Analysis 
Software (SAS) to compute statistics from the data. Statistics included basic statistical tables and 
a regression model. SAS was also used to calculate the distance between biotechnology 
companies and their associated venture capital investors. 
This paper proceeds as follows. Chapter 2 contains the literature review of venture 
capital, biotechnology, and the relationship between them. Chapter 3 presents the hypotheses, 
data, and methodology. Chapter 4 provides statistics, including a regression model, analysis, and 
results. Chapter 5 presents a conclusion of the work. 
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CHAPTER 2 
REVIEW OF LITERATURE 
 While investigating biotechnology and venture capital firms for this study, it was found 
that very little work has been completed directly relating to this subject. Regardless, a variety of 
periodicals were used to examine this topic. This chapter includes a brief history of venture 
capital, the significance of venture capital investments, the prosperity of the biotechnology 
industry, biotechnology dependency on venture capital investments, and the spatial influence on 
venture capital investments. Each area is essential in the understanding of the investment 
relationship between venture capital firms and the biotechnology industry. 
Brief History of Venture Capital 
 Venture capital can be defined as a unique form of capital that involves the exchange of 
funds for an ownership stake in a firm (Florida & Smith, 1993). According to Kortum and Lerner 
(1998), venture capital can be defined as equity or equity-linked investments in young, privately 
held companies, where the investor is a financial intermediary who is typically active as a 
director, advisor, or even as manager of a firm. Venture capital funds are typically private equity 
capital invested by institutional investors used to fund new or growing businesses. Funds are 
usually invested in high-growth, high-risk, but potentially highly-profitable companies in 
exchange for preferred shares in the invested companies (Black & Gilson, 1998). This preferred 
stock converts into liquid common stock or cash at one of two major exit points: an Initial Public 
Offering (IPO) or an acquisition by another entity (Hand, 2007). Exits through IPOs are reached 
when a firm becomes public traded. Companies that reach IPO bring their investors high profits 
through the selling of shares. Exits through acquisition means the company was purchased by 
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another firm. In the case of biotechnology, these firms are typically acquired by larger 
biotechnology companies or pharmaceutical companies (Cumming, 2002).  
 The first modern venture capital firm established in the United States was the American 
Research and Development (ARD) in 1946. It was formed MIT President Karl Compton, 
Harvard Business School Professor Georges F. Doriot, and other local business leaders (Kortum 
& Lerner, 1998). The ARD was structured as a publicly traded closed-end firm, whose shares 
trade from investor to investor on an exchange like an individual stock. Selling shares to 
investors allows ARD and other venture capital firms to raise capital up front. For 26 years ARD 
invested in high-risk, emerging companies that were based on technological development. Their 
most profitable investment came in 1957 when ARD invested $70,000 in Digital Equipment 
Company, which grew in value to $355 million. As a result of their success, the ARD stimulated 
competitors in the biotechnology industry the following decade (Gompers, Lerner, Blair, & 
Hellmann, 1998).  
 Most United States venture capital firms remained publicly traded and marketed to 
individuals due to a shortage of investments from institutional investors in the 1950s-1970s.  
Many firms raised money through closed-end funds or small business investment companies 
(SBICs). SBICs are federally guaranteed risk-capital pools that proliferated during the 1960s as a 
result of the United States’ fear of lagging behind in technological competitiveness, especially 
after the Soviet Union launch of Sputnik in 1957. Regardless of the strong market for SBICs 
during this time, some firms became interested in making a greater profit by taking greater risks 
than government guarantees created. This resulted in the collapse of the sector (Gompers & 
Lerner, 2001).  Also, during this time period the United States began to see the emergence of 
venture capital limited partnerships, which primarily invest the financial capital of third-party 
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investors in projects that are extremely risky for the standard capital markets or bank loans. 
Investors included wealthy individuals, pension funds, financial institutions, insurance 
companies, and other sources that were interested in investing in high-risk businesses but lack 
the ability to do so independently (Powell et al., 2002). Investors in return become limited 
partners with restricted liability in the venture capitalist firms. The first limited partnership was 
formed in 1958 with the partnership of Draper, Gaither, and Anderson and imitators followed. 
Although venture capital limited partnerships were on the rise in the United States, they still 
accounted for a marginal section of the venture pool during the 1960s and 1970s (Gompers, et al. 
1998). 
 Two significant contributions to the venture capital industry that assisted in its continued 
growth overtime include funding and organization. The 1970s and early 1980s brought about a 
dramatic increase in funding opportunities. This increase was the result of the passing of the 
1979 amendment, also known as “prudent man” rule, which governed the use pension funds. 
Prior to 1979, the Employee Retirement Income Security Act (ERISA) restricted pension funds 
from investing large amounts of money into high-risk asset classes. After the ruling of the 1979 
amendment, pension funds significantly increased the amount of venture capital funds. In 1978, 
$424 million was invested in new venture capital funds and pension funds only accounted for 
15%. In 1986, more than $4 billion in capital was invested and pension funds accounted for more 
than half of all contributions (Kortum & Lerner, 1998).  
Also, there has been a significant change in the dominant organizational form in the past 
20 years. From the start of ARD in 1946 until the early 1980s, publicly traded closed-end funded 
firms dominated the organizational form. The collapse of the SBIC sector and the dramatic 
increase in venture capital funds, opened the door for the limited partnership to become the new 
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dominant organizational form. Limited partnerships have several advantages, one of which is 
taxes. Capital gain taxes are not paid by the limited partnership, instead they are paid only by the 
taxable investors. This makes limited partnerships very attractive to tax-exempted institutional 
investors, who remained uninvolved until the early 1980s (Gompers & Lerner, 2001).  
Venture capital investment in the United States resembled a roller coaster pattern 
beginning in the 1970s and reached its peak from 1999 to 2000, mirroring the stock market 
bubble of the Internet industry during the same period (Green, 2004). During this time period, 
venture capital funds increased from $3.34 billion in 1990 to $103.85 billion in 2000 and the 
number of firms increased from 1,317 in 1990 to 5,458 in 2000 (Peng, 2001). Funding during 
these years was predominantly concentrated in the Internet and telecommunication industries, 
which accounted for 39% and 17% of all venture disbursements in 1999 (Lerner, 2002). Short 
lived, the bursting of the Internet bubble resulted in dramatic declines in investment levels and is 
thought to have altered the investment patterns of the industry. Today, there is continued 
emphasis being placed on corporate-sponsored venture capital in place of the independent firms 
that now dominate the industry. Also, during the bubble many venture capitalists invested in 
ideas with little assurance, while many of them watched as their capital in the boom ultimately 
failed. After the bubble collapsed, no longer will venture capitalist throw money at grandiose 
promises about potential discoveries or new technology platforms (Weintraub, 2004).  
Significance of Venture Capital Investments 
 Venture capitalists funds in the United States are predominately invested in early-staged 
ventures and high-technology industries. Venture capital plays a dominant role in several 
important and growing sectors where the United States is viewed as a world leader, including 
biotechnology (i.e. Genentech), personal computers and workstations (i.e. Apple and Compaq), 
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personal computer software (i.e. Harvard Graphics), and semiconductors (i.e. Intel) (Black & 
Gilson, 1998).  
Venture capital investment is often called smart money because it provides more than just 
money to portfolio companies (Cuny & Talmor, 2005). In addition to capital, the venture capital 
investments provide the portfolio companies with management assistance, intensive monitoring 
of performance, and reputational capital. With management assistance, the venture capital firms 
have experience in developing startup companies, providing market knowledge, locating and 
recruiting workers, and assisting a company through prototype development to production, 
marketing, and distribution. With intensive monitoring of performance, they maintain control 
rights, voting rights, as well as greater board representation that investors use if they feel the 
entrepreneur is driving the company in the wrong direction. With reputational capital, venture 
capital financing enhances the portfolio company’s credibility with third parties by providing 
talented managers, suppliers, and customers (Gilson & Black, 1999). Venture capitalist 
knowledge and experience greatly increases the chances for a portfolio company to become 
successful. 
Although many venture capital firms are large enough to effectively diversify their funds 
to several portfolios, funding is an extremely competitive business with free entry (Cochrane, 
2001). In other words, because venture capital funding is so competitive, biotechnology 
companies can freely send proposals to several investors in search for funding. According to 
Kortum and Lerner (1998), only one percent of those firms that submit business plans to venture 
organizations have been funded. In other words, the rejection rate for these proposals is 
extremely high (99%) (Powell et al., 2002). If funding occurs, funds are typically distributed in 
two ways: milestone financing or round financing. Milestone financing includes both an 
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immediate funding and a commitment for additional investment later. Future funds have a 
predetermined price and are only distributed to a portfolio company if it meets pre-specified 
technological or operational goals. Round financing has no pre-commitment to invest beyond the 
current funding needs. Future investments are priced based on the status of the portfolio 
company at the time funding is desired. Both milestone and round financing have their 
advantages and disadvantages and each particular firm has to determine the best method for their 
company (Cuny & Talmor, 2005). Tian (2008) finds biotech firms located closer to their 
investors receive fewer rounds of investments in comparison to those firms located farther away. 
Firms located closer to their investors receive a greater overall amount of capital, have greater 
chance of IPO exits, and manage to outperform their distant competitors. In other words, the 
greater amount of rounds, or sequences, a biotech company receives is not necessary related to 
the amount of capital it receives. 
With funding comes a specific contract with portfolio companies. These contracts are 
heterogeneous; in other words, they vary from one company to another and depend on other 
factors such as the success of those companies. These contracts include control rights, veto 
rights, provisions for different contingencies, liquidations rights, among other things (Cumming, 
2002). Most of these rights are transferable. If a company performs poorly, the venture capitalist 
obtains full control; however, if a company performs well, the venture capitalist retains its cash 
flow rights but relinquishes most of its control and liquidation rights (Kaplan & Stromberg, 
2000). Because monitoring is costly and cannot be performed continuously, the venture capitalist 
will periodically check the project’s status and preserve the option to abandon. If the portfolio 
company does poorly and continues to do so, the venture capitalist may choose to cut off any 
new financing (Gompers, 1995).  
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Prosperity of the Biotechnology Industry 
 According to the Pricewaterhouse Coopers (2007), biotechnology can be defined as 
developers of technology promoting drug development, disease treatment, and a deeper 
understanding of living organisms, industrial biotechnology, biosensors, biotechnology 
equipment, and pharmaceuticals. In other words, biotechnology is a developing science in which 
scientific and product development processes are collaborative (Oliver, 2004). Biotech firms are 
highly dependent on ideas, discoveries, and patents they generate through large research and 
development (R&D) expenditures, that are some of the most intensive of all businesses (Hand, 
2007). 
  Commercial bioscience began in 1974, when Cohen-Boyer patented their work that 
provided the means to manipulate genetic material to produce commercial products. These 
genetic commercial products are more naturally accepted by the human body and its 
environment (Feldman, 2000). This work sparked biotechnology as a commercial industry. 
During the early years, from the 1970s to the late 1980s, biotech industries were very small start-
ups that relied on external support. Lacking the skills and resources needed to bring new 
innovations to the market, they became involved in complex relationships with research-oriented 
universities (most notably: MIT, Harvard, Stanford, among others) and large pharmaceutical 
companies. Hundreds of small science based firms were founded adjacent to universities by the 
late 1980s. By the end of the decade, several of those firms (Biogen, Genentech, Immunex, etc.) 
became large and formidable organizations (Owen-Smith & Powell, 2004).  
As biotechnology firms continued to locate themselves in this pattern, this resulted in the 
beginning formations of biotechnology clusters in key U.S. regions (Sainsbury, 1999). The most 
notable clusters include the San Francisco Bay Area and the Boston Metropolitan Area, which 
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stand as the largest and most commercially successful biotechnology regions in the world. Other 
notable clusters include San Diego (CA), Raleigh (NC), Seattle (WA), and Denver (CO). The 
success of these clusters is dependent on a unique combination of dense social networks and 
geographic co-location (Porter, 2005). In other words, within these clusters, there are extensive 
relationships between biotech firms and public research organizations, including universities, 
government laboratories, and research hospitals (Porter, Whittington, & Powell, 2005). These 
spatial concentrations grant several advantages, including transportation costs, access to skilled 
labor markets, communication markets, sophisticated customers, and access to technology. The 
advantages of location then are very much based on access and information. These advantages 
coupled with the success of biotech clusters draw new entrants to these key U.S. regions (Powell 
et al., 2002). 
Biotechnology Companies Dependence on Venture Capital Investments 
 Biotechnology is considered a high-technology, high-risk, potentially high-rewarding 
industry. This makes receiving financing through traditional sources such as banks, government 
funds, private investors, and large pharmaceutical companies extremely difficult. Thus, biotech 
companies look to venture capital firms for funding (Ang, 2006). A number of studies have 
shown that the presence of local venture capital has an important positive impact on the 
formation of new firms (Stuart & Sorenson, 2003; Zucker, Darby, & Brewer, 1998). 
The prototypical young biotech firm is in an intense R&D race against competitors to 
discover and patent a new drug. Consequently, these firms have large capital needs over a 
continuous period of time. Failure to receive funds can result in the termination of a project, thus 
giving competitors the advantage to make initial discoveries and receive patents (Hand, 2007). 
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Some new biotechnology companies can require millions to 10s-of-millions of dollars to get 
started (Lee & Dibner, 2005). Thus, some biotechnology companies depend entirely on venture 
capital for their existence (Weeks, 2005). These venture capitalists funds can range in size from 
about $20 million to billions of dollars (Lee & Dibner). Eventually, the capital needs of a firm 
become so large that they can only be satisfied via IPO or a buyout from a large pharmaceutical 
company (Hand). If a biotech firm succeeds by reaching IPO or being acquired, the venture 
capitalist can reap profits of 5 to 10 times its initial investments or possibly more. However, 
venture capitalists can lose their capital investments if the portfolio company fails in reaching 
IPO or fails in being acquired (Lee & Dibner).  
 Because venture capital funds are limited and competitive, biotech companies will submit 
proposals to several venture capital firms to increase their possibilities. Biotech firms may 
receive funding from multiple venture capitalists, whether for the same project or for discrete 
projects. The same is true for venture capitalist who are likely to invest in other biotech firms, 
including some that may be competitors in a particular area (Powell et al., 2002).  
 Again, venture capital funds are often called smart money because it plays a dual role. In 
addition to providing capital, venture capitalists provide coaching, guidance, connections with 
suppliers, customers, and so on (Cuny & Talmor, 2005). Thus, venture-backed biotech firms 
grow more rapidly and are more flexible than do their competitors that do not receive venture 
capital funding or only receive public funds (Hand, 2007).  
Spatial Influence on Venture Capital Investments 
Regardless of the complication of networks, geography plays an essential role in the 
biotechnology industry (Owen-Smith & Powell, 2004). As Porter, Whittington, and Powell 
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(2005) have pointed out, biotechnology firms are located in a small number of U.S. regions 
because of the extensive relations between firms and public research organizations. 
From the 1970s to the late 1980s, biotech industries were very small start-ups located 
near research-oriented universities because they lacked the skills and resources needed to bring 
new innovations to the market (Owen-Smith & Powell, 2004). This resulted in the formations of 
heavily concentrated biotechnology clusters throughout the United States. For example, by the 
beginning of the 21st century, the Kendall Square neighborhood in Cambridge, Massachusetts 
became the largest single, geographically concentrated cluster of biotech firms in the world 
(Porter, Whittington, & Powell, 2005). The formation of clusters sparked a shift in the 
geographic location of venture capital companies from financial centers to these high-technology 
regions. This shift was initially made to reduce the high-risks of investing in high-technology 
companies (Florida & Smith, 1993). By locating within these regions, venture capitalists can 
monitor their investments and the portfolio company’s progress more effectively, while 
significantly reducing transaction, transportation, and other costs associated with distance (Tian, 
2008).  According to Lerner (1995), venture capital firms with offices within five miles of the 
portfolio company are twice as likely to serve as board members as those located over a 100 
miles away.  
The spatial pattern of venture capital investing became more complicated in 1999, as they 
began to disburse their funds more widely. A study completed by Kenney and Patton (2005) 
found that only around 25% of venture capitalists invest in local firms. Another study completed 
by Powell et al. (2002) found that majority of the biotechnology companies in their sample 
receive local venture capital funding. Venture capitalists located within high-technology centers 
tend to invest locally (Florida & Smith, 1993). Venture capitalists outside the biotech clusters 
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(i.e. New York and Chicago) are significantly more likely to export their capital to non-local 
companies that are located within these high-technology clusters (Kenney & Patton, 2005).  
Today, it is not unusual for venture capitalist to ask academic scientists if they have any 
ideas that are ready for product development in the United States. If so, there would be no 
surprise if a newly created firm would be located close to the university. This way, scientists can 
resume their faculty association and serve on the board of these newly created firms (Schweitzer, 
Connell, & Schoenberg, 2004). If scientists were located outside of the biotech clusters (i.e. New 
York, Los Angeles, Houston, etc.) they would be more likely to serve on the company’s board 
from a distance (Powell et al,. 2002).  
 By investigating the recent literature on biotechnology and venture capital firms, this 
research used a variety of periodicals to examine the topic. The subjects were diverse and 
covered a brief history of venture capital, the significance of venture capital investments, the 
prosperity of the biotechnology industry, biotechnology dependency on venture capital 
investments, and the spatial influence on venture capital investments. Background information of 
investment relationship between venture capital firms and biotechnological industries are vital 
for contributing to further research. 
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CHAPTER 3 
HYPOTHESES, DATA, AND METHODOLGY 
 The study area for this research includes all data records of venture capital firms 
investing in biotechnology companies from 1995 to 2005 within the United States. Once the 
study area was defined, the records of investments from venture capital to biotechnology were 
accumulated into one large database. Another database was complied containing the names and 
addresses of the venture capital firms that invest in these biotech companies. Upon completion of 
the databases, GIS was used to locate and map both the venture capital firms and the 
biotechnology companies. SAS statistical software was then used to calculate the distance 
between venture capitalists and biotechnology companies and provide statistically information 
about the data. 
Hypotheses 
This study’s initial focus is on whether or not variables influence the amount of capital a 
biotech company receives from its venture investors.  
Several papers have focused on the importance of distance and its influence on 
investments, most notably Tian (2008), Powell et al. (2002), Coval and Moskowitz (2001), and 
Lerner (1995). These authors found that the closer a biotech company is to its investors, the 
greater amount of capital it would receive. This idea is based on the thought that venture capital 
investors would feel safer investing large amounts of capital into biotech companies they can 
monitor closely and efficiently. The first hypothesis is: 
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 Hypothesis #1 Research: The closer the spatial relationship between venture capital 
investors and biotechnology companies, the more capital biotechnology companies receive from 
those venture capital investors.  
Hypothesis #1 Null: The distance between venture capital investors and biotechnology 
companies has no effect on the amount of capital invested in those companies. 
Physical distance between investor and investee greatly influences a venture capital 
firm’s decision when investing. Venture capitalists have to take into consideration their 
monitoring costs, which include visiting the firm, attending board meetings, being engaged in 
daily operations, talking with suppliers and employees, and assessing the local market condition. 
Because distance increases cost, distance is likely to limit a venture capitalists decision when 
investing. (Coval & Moskowitz, 2001). Studies completed by Tain (2008) and Lerner (1995) 
show that firms located in closer proximity to their venture capital investors receive more 
money, outperform, and have a greater possibility of an IPO exit than firms located farther away. 
In addition, Powell et al. (2002) reported that venture capital supported companies were three 
times more likely to generate patents than their competitors who receive no venture capital 
support. Thus, testing this hypothesis will provide insight on the importance of distance in 
accordance to the amount of capital a biotechnology companies receives from its venture capital 
investors. 
A previous study completed by Sorenson and Stuart (2001) has shown that a biotech’s 
stage of development can influence the amount of capital it receives from venture capitalists. 
Biotech companies in earlier stages of development search for capital to fund new projects, while 
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companies in later stages of development require more capital to cover the costs of production, 
marketing, and distributing its product. The second hypothesis is related to this issue. 
Hypothesis #2 Research: Biotech companies in later stages of development receive 
more capital from their venture capital investors. 
Hypothesis #2 Null: Stage of development has no effect on the amount of capital a 
biotech company receives. 
Stage of development can influence the amount of capital a biotech company receives. 
Biotech companies in their first stage of development, known as the Start-Up/Seed Stage, have 
little to no experience. Due to the lack of experience and track records, earlier stage biotech 
companies can expect to receive smaller quantities of capital as opposed to a biotech companies 
in their later stages (Sorenson & Stuart, 2001). According to Sorenson and Stuart, biotech 
companies in their later stages of development have extensive experience and have become 
known, thus increasing the possibility of them attracting new/more venture capitalists firms.  
A study completed by Tian (2008) explains that the amount of capital a biotech company 
receives can be influenced by its financial sequence. In respect to this idea, it was hypothesized 
that a biotech company would receive a greater amount of capital if it received several financial 
sequences. This thought was based on the idea that the more financial sequences would result in 
more capital for a biotech company. The third hypothesis is related to this issue. 
Hypothesis #3 Research: Biotech companies with a greater number of financial 
sequences receive more capital from their venture capital investors. 
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Hypothesis #3 Null: The number of financial sequences biotech companies receive does 
not affect the amount of capital they obtain. 
 Financial sequence can greatly influence the amount of capital a biotech company 
receives because it has to do with the total number of times a venture capitalists invests capital 
into a particular biotech company. Biotech companies that are located farther away from their 
investors have a tendency to receive more rounds of financing than a biotech company located 
closer to its investor (Tian, 2008). According to Tian (2008), although biotech firms located 
closer to its investors receive fewer rounds of investment, they still receive a greater overall 
amount of capital and manage to outperform their distant competitors. This may be the case 
because venture capital firms are not enthusiastic about investing large amounts of capital into 
companies they are not capable of monitoring efficiently. 
Data 
Data were gathered through the Pricewaterhouse Coopers’ Money Tree Report website. 
The Money Tree Report stands as the only industry-endorsed research of its kind, providing a 
quarterly report of venture capital investment activity in the United States. The website offers 
quarterly data beginning from the first quarter of 1995 until today. For the purposes of this study 
the focus will be on venture capital investment data that begins with the first quarter of 1995 and 
extends to the fourth quarter of 2005, totaling 11 years or 44 quarters of data. 
After logging into the website, the Money Tree Report provides an aggregated bar graph 
of all quarterly data and the options to limit the search by region, state, industry, stage, and 
financing sequence. By clicking on any of the quarters, the website exhibits a list of investee 
companies by quarter in alphabetic order. The Money Tree Report offers the options of selecting 
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any of the companies and provides detailed information of the particular company selected. The 
type of information the Money Tree Report offers includes the biotech companies name, address, 
region, contact information, capital received, financing sequence, stage of development, type of 
industry, description of industry, and all the investors in that company for the quarter. Also, the 
Money Tree website goes one step further by providing venture capital firm details for each 
company on a quarterly basis. Venture capital firm details include: name, address, region, 
contact information, website, email, and other investments, if any, for that same quarter. The 
predominate interest in this research is on the amount of capital a biotech company receives and 
its association with the financial sequences, stage of development, number of investors, region, 
and the locations of both the biotech company and its investors. The Money Tree Report website 
has more than a sufficient amount of data, allowing the possibility to explore several different 
questions and options. The only task will be grouping all 44 quarters of data into one large 
dataset.  
Combined, the 44 quarters of data totaled 3,219 records of investments of venture 
capitalists in biotechnology firms. Due to the number of companies with undisclosed 
information, which included unknown locations of biotechnology and investor firms, some 
records were eliminated from the database. The same was true for a minority of biotechnology 
companies that were listed but actually received no capital. Because the goal of this research was 
to look at the proximity and amount of investment flowing from venture capital firms to 
biotechnology companies, it was necessary to delete these records. After cleaning the data and 
deleting the inadequate records, this left a total of 2,890 records of investments of venture 
capitalists in biotechnology companies.  
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A basic statistical table was created on the 2,890 biotech records to see the overall results 
(see Table 1, page 41). This table displays the mean, standard deviation, median, minimum, and 
maximum for all the records in accordance to the amount of investment ($), number of investors, 
financial sequence, stage of development, minimum distance (in miles), and international 
investors. To better understand the variables and their effect on investment capital, one has to 
understand the parameters that the Money Tree Report uses when disclosing information. For 
instance, the Money Tree Report employs 18 geographical areas to represent the regions of the 
United States. These regions include:  
 1) Alaska, Hawaii, and Puerto Rico 10) Philadelphia Metro 
 2) Colorado 11) Sacramento and Northern California 
 3) DC and Metroplex 12) San Diego 
 4) LA and Orange County 13) Silicon Valley 
 5) Midwest 14) South Central 
 6) New England 15) Southeast 
 7) New York Metro 16) Southwest 
 8) North Central 17) Texas 
 9) Northwest 18) Upstate New York 
 
The website defines a financial sequence as “cash for equity investments as the cash is actually 
received by the company (also called a tranch)” (Money Tree Report, 2007, para 3). According 
to the gathered data, financial sequence spans from 1 to 18, with majority of the records having a 
financial sequence between 1 and 3. Finally, the Money Tree website breaks stage of 
development into four groups. The four stage of development groups include:  
1) Start-Up and Seed Stage – company is probably not fully operational, products and 
services are under development, and have been in existence for less than 18 months;  
2) Early Stage – company is probably in testing or pilot production, products and services 
could possibly be commercially available, and have been in existence for less than 3 
years;  
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3) Expansion Stage – products and services are in production and commercially available, 
significant revenue growth, and have been in existence for more than 3 years; and,  
4) Later Stage – products and services are widely available, company is generating on-going 
revenue, and may include spin-outs of operating divisions of existing and established 
private companies. 
Methodology 
The research only includes biotechnology companies (biotech) located within the United 
States. Data, including the locations of venture capitalist and biotech companies, were gathered, 
analyzed, and mapped to show the correlation and spatial relationship between venture capitalists 
and biotech companies. The study focuses both on the spatial relationship between venture 
capitalists and biotech companies at the individual level and at the regional level. 
Biotech and venture capital data were gathered through Pricewaterhouse Coopers’ Money 
Tree Report. The data were collected by means of copying and pasting. Every biotech company 
for every quarter spanning from 1995 to 2005 was copied and then pasted into an Excel database.  
Biotech information included the name, address, region, contact information, website, email, 
amount of investment, financing sequence, stage of development, type of industry, description of 
industry, and all the investors of that company. The 11 years of gathered data totaled 3,219 
entries of investment. A significant number of records were deleted because they contained 
undisclosed information. In other words, the undisclosed records were deleted because they 
exclude the biotech companies name, address, financial sequence, stage of development, and 
quite often, who are the investor(s). Because the objective of this study is to look at the spatial 
relationship between biotech companies and venture capital firms, it was necessary to delete 
these records.  
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Also, a small number of biotech records were deleted from the database because their 
received investment was zero. Thus, they pose no significance in this study and the objective of 
this study. Insufficient data resulted in the deletion of 329 biotech records, leaving a total of 
2,890 companies that contain the necessary information.  
After the biotech companies were complied, it was necessary to gather information on the 
venture capitalists. Venture capitalist information was gathered through Pricewaterhouse 
Coopers’ Money Tree Report. The data included the venture capital companies name, address, 
region, contact information, website, email, and all the invested companies. Venture capital 
information was gathered by copying the data and pasting it into an Excel database. There were 
854 venture capital companies collected from the Money Tree Report. During the copy and paste 
process, all undisclosed venture capital companies were excluded from the database because they 
lacked vital information. With the completion of both the biotech and venture capital databases, 
the next step was to map their locations.  This was completed by opening both database files in 
ArcGIS, GIS software developed by Environmental Systems Research Institute, Inc. (ESRI).  
Geographic Information Systems (GIS) 
In order to find out if the spatial relationship between biotech companies and venture 
capital firms was significant or not, the term “local” has to be defined. The locations of biotech 
and venture capital companies were mapped in accordance to their zip codes. An investment was 
local if the investment(s) from the venture capital firms are within 60.4 miles, or within an hour’s 
drive, of the invested biotech company’s zip code. Thus, any venture capitalist investing in a 
biotech company that was 60.5 miles or further was considered non-local. 
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Both the biotech and venture capital database files were added to ArcMap 9.2, a program 
of ESRI’s ArcGIS software package. There are several ways to display the locations of the 
biotech and venture capitalist companies. Because biotech and venture capital companies were 
mapped based on their zip codes, it was crucial to find a way to display them accurately. 
Considering the size of the files and their distribution across the United States, it was far more 
efficient and accurate to display the coordinates of the companies as opposed to geocoding the 
addresses of the files. The coordinates were necessary to display these files by zip code area. 
This was completed by downloading the entire United States zip code shapefile from the Census 
Bureau website. The U.S. zip code shapefile was added to ArcMap 9.2 and displays as a point 
layer containing 41,588 different zip codes across the country. The U.S. zip code file also 
included the longitudes and latitudes associated with each zip code. The longitudes and latitudes 
for each biotech company was obtained by “joining” the biotech dataset table with the U.S. zip 
code attribute table. To perform a “join” in ArcMap, two tables have to have some type of 
commonality. In this case, the tables were “joined” together using the zip code field. The results 
of the “join” table displayed each biotech company’s zip code with its corresponding 
coordinates. In order to map the locations of the venture capital firms, the same type of joining 
feature was performed between the venture capital database and the U.S. zip code attribute table.  
With the use of ArcMap 9.2, several maps were created from the data. The first map 
(Figure 1) displays the locations of biotech companies across the United States from 1995 - 
2005. The second (Figure 2) and third (see Figure 3, Appendix A) maps focus on the locations of 
venture capital firms across the world and the United States, respectively. Two other maps were
  
Figure 1: Displays the locations of biotechnology companies that receive some degree of venture capital investment 
between 1995 and 2005. 
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Figure 2: Displays the locations of Venture Capital Firms that invested some amount of capital into the Biotechnology 
Industry. 
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created showing a zoomed in picture of the San Francisco Bay Area and Boston Metropolitan 
Area maps (see Figures 4 and 5, Appendix B and C) display two side-by-side maps showing the 
locations of the biotechnology companies and venture capital firms in these areas. Maps (see 
Figures 6 and 7, Appendix D and E) on the locations of biotech companies in from two periods 
(Q1/1995-Q2/2000 and Q3/2000-Q4/2005) were created, as well as a map (see Figure 8, 
Appendix F) to show the percent biotech growth between these periods. Other maps (see Figures 
9-11, Appendixes G, H, and I) include the locations of biotech companies that receive at least 
$10 million, $25 million, and $50 million from their venture capital investors in one funding 
period. 
Once the companies and the venture capitalists were mapped, the distances between 
biotech companies and their closest investor needed to be calculated. This distance will help 
explain the investment flow between venture capital investors and their biotech companies.  
Statistical Analysis Software (SAS) 
All statistics completed during this research was performed using SAS’s Statistical 
Software 8.2. The objective of using SAS is to calculate a minimum distance, create basic 
statistical tables, and perform a regression based on the study’s dependent and independent 
variables. 
Both the biotech and venture capital databases used in ArcMap 9.2 were imported into 
the SAS program. The tables were examined to make sure they contained all of the information. 
Because the tables already contained the coordinate information, it was simple to calculate a 
‘minimum distance’ – the distance between a biotech company and its closest investor. This was 
completed by using the Great Circle Route formula: 
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 Where,  represents the geographical latitude and longitude of two points,  
represents the longitude difference, and the (spherical) angular difference/distance. This 
calculation will help to understand if distance has an effect on the amount of money venture 
capital firms invest.  
 It was noticed that the biotech database needed some additional cleaning. A small number 
of the biotech records were between stages of development or financial sequences. As a result, 
these records listed both stages or sequences. To prevent confusion and to keep consistency, this 
needed to be resolved. For stage of development, there were initial four stages in this study 
(Start-up and Seed, Early, Expansion, and Later), which became six groups for the purposes of 
this study. The six groups include Start-Up and Seed, Early, Early and Expansion, Expansion, 
Expansion and Later, and Later. For financial sequence, if a biotech record listed more than one 
sequence, the first listed sequence was used to represent the company’s financial status. With this 
information corrected, it was time to run statistics tables and a regression model properly and 
accurately.  
The SAS program was used to create five tables based on the biotech database. The first 
table (Table 1) shows some basic statistically information on all 2,890 biotech records. The 
second table (Table 2) displays the overall number of investment contracts by region. The second 
table also shows the difference and percent change between the first 22 quarters (Quarter 1 of 
1995 – Quarter 2 of 2000) and the last 22 quarters (Quarter 3 of 2000 – Quarter 4 of 2005). The 
third table (Table 3) displays the local vs. non-local count and average capital investments 
broken down by the stages of development, financial sequences, and domestic vs. international 
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investments. The fourth table (Table 4), similar to the second table, presents the total amount of 
capital invested by region. Also, Table 4 shows the difference and percent change in invested 
capital from the first 22 quarters to the last 22 quarters. The final table (Table 5) represents the 
regression, where capital signifies the dependent variable and other biotech characteristics are 
tested as independent variables to test their significance. 
Regression Model 
Biotechnology companies receive varied amounts of capital from their venture capital 
investors. Thus, a regression model was used to find the influence variables have on the amount 
of capital a biotech company receives. The regression formula: 
Y  =  a0 + b1 X1 + b2 X1 + b3 X1 + b4 X1 + b5 X1 + b6 X1 + b7 X1 + b8 X1 + e 
where, the amount of capital a biotechnology company receives is the dependent variable (Y). 
Independent variables include Financial Sequence (X1), Stage of Development (X2), Minimum 
Distance (X3), Local Investors (X4), International Investors (X5), Boom (X6), New England (X7), 
and California (X8). It is believed that each of these variables has some effect on the amount of 
capital a venture capital firm will invest into a biotechnology company. 
 Before the regression model was executed, a log transformation was performed on the 
dependent variable. This was performed based on the dependent variables being heavily skewed 
and the log transformation was used to reduce the skewness and better fit the data into a normal 
distribution. The regression model is as follows: 
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Log (Capital)  =  a0 + b1 Financial Sequence + b2 Stage of Development  
+ b3 Minimum Distance + b4 Local Investors  
+ b5 International Investors + b6 Boom + b7 New England  
+ b8 California + e 
where Financial Sequence will show if the number of financial rounds a company receives 
affects the total amount of capital it receives. In this research, biotech companies’ financial 
sequence ranges between 1 and 18. This variable will explain how financial sequences affect the 
amount of capital a biotech company receives. The Stage of Development variable will show 
whether there is a change in the amount of capital a biotech company receives based on its stage 
of development. The Minimum Distance variable will explain whether distances between a 
biotech company and its closest venture capital investor influence the amount of capital a 
company receives. The Local Investors variable was used to describe how local investors 
influence the total amount of capital a biotech company receives from its investors. In other 
words, this variable will explain whether biotech companies that receive local funding obtain a 
greater amount of capital than those companies that receive no local funding. 
The other variables in this research are dummy variables that were used to locate any 
existing or missing information that might influence the results. International Investors describe 
how foreign investments affect the total amount of investments a biotech company receives. 
Biotech companies that receive foreign investments were issued a value of one, and companies 
that received no foreign support were issued a value of zero. The Boom dummy variable 
represents the spike in venture capitalists investments during 1999 to 2000. Biotech companies 
were issued a value of one if they received venture capital investments during this time period 
and the others were issued a value of zero if they received an investment outside this period. 
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Dummy variables, New England and California, represent the two largest biotechnology clusters 
in the world. With this in mind, both regions were issued as variables during the regression 
model. The New England variable, biotech companies located within the region received a value 
of one, while biotech companies outside of the New England region received a value of zero. 
This worked similarly for the California regions; biotech companies inside the California regions 
received a value of one and those located outside the region received a value of zero. 
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CHAPTER 4 
RESULTS 
 Basic statistical tables and a regression analysis were used to test the outcomes of the 
hypotheses. Table 1 presents summary statistics of the overall biotech database file. This file 
includes 2,890 records of investment from venture capitalists to biotech companies. As the 
results below indicate, a biotech company receives an average of $9,816,885 million from its 
venture capital investors per contract. Of the 11-year span (1995 – 2005), Biosynthesis, Inc. from 
Lewisville, TX received the smallest quarterly investment of $3,000 (1996 – Quarter 1) and 
Reliant Pharmaceuticals LLC located in Liberty Corner, NY received the largest quarterly 
investment of $161,000,200 (2002 – Quarter 1). The average biotech company receives 
investments from 3 to 4 venture capital investors. Considering all biotech companies with 
undisclosed investors were deleted, this means all biotech companies in this database have at 
least one investor. The maximum number of investors a single biotech company received was 19 
by Renovis, Inc. (2003 – Quarter 3) and Memory Pharmaceuticals Corporation (2002 – Quarter 
1).  
The typically biotech company maintained an average financial sequence of 3 investment 
rounds per investor. According to the Table 1 more than 2/3 of the records were listed having a 
financial sequence from 1 to 3. Only a handful of companies listed a financial sequence of 10 or 
greater. Also, during these 11 years, the typically biotech company was in its expansion stage of 
development. A majority of the biotech companies in this study are in an early to expansion 
stage of development. Biotech companies are an average of 44.65 miles away from their closest 
investor, with Sequenom, Inc. in San Diego, CA having the furthest minimum distance of 
Table 1 
 
Overall Biotech Firm Statistics (1995 - 2005) 
 
N = 2890 
Variable Mean Standard Deviation Median Minimum Maximum 
Capital (in Millions of Dollars) 9.816 13.477 5.100 0.003 161.0002
Number of Investors 3.643 2.611 3.000 1 19
Financial Sequence 2.970 2.217 2.000 1 18
Stage of Development 3.259 1.631 3.400 1 6
Minimum Distance (in miles) 44.653 49.922 21.170 0 215.072029
Local Investors 0.834 0.371 1 0 1
International Investors (dummy) 0.0813 0.273 0 0 1
New England (dummy) 0.178 0.383 0 0 1
California (dummy) 0.345 0.476 0 0 1
 
Note. This table presents summary statistics for the biotech database table. The table includes 2,890 biotech investment records listed from 1995 – 2005. These 
records included several biotech variables including capital, number of investors, financial sequence, stage of development, minimum distance, local investors, 
international investors, New England, and California. The table shows the calculated mean, standard deviation, median, minimum, and maximum for each 
variable. 
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215 miles from its closest investor and several biotech companies receiving venture capital 
funding from the same zip code.  
Table 2 provides insight about biotech firms aggregated by U.S. regions. The Money 
Tree Report divides biotech companies into 18 geographic regions. The table lists the overall 
number of contracts from 1995 to 2005. The table also shows the number of investments located 
in each region for the first 22 quarters - Quarter 1 of 1995 to Quarter 2 of 2000 (Q1/1995-
Q2/2000), and the last 22 quarters - Quarter 3 of 2000 to Quarter 4 of 2005 (Q3/2000-Q4/2005), 
and the percent difference in change over these two periods. As the literature noted, the largest 
biotech regions exist in New England and California. The four largest biotech regions (Silicon 
Valley, LA and Orange County, San Diego, and New England) in this research are located within 
the California and New England areas. Combined, the four regions made up greater than 50% of 
the total amount of investment contracts in the sample (1,506 out of 2,890 contracts). In 
accordance to the amount of investment contracts, the smallest biotech regions include Alaska, 
Hawaii, and Puerto Rico region, Sacramento and Northern California region, Upstate New York 
region, and South Central region (Oklahoma, Kansas, and parts of Texas). Together, those four 
regions only represent 40 out of 2,890 contracts. All 18 regions, with the exception of Colorado 
and Texas, experienced some type of positive growth from Q1of 1995 - 2 of 2000 to Q3 of 2000 
- 4 of 2005.  
There are several regions in Table 2 that experience a significant increase in the amount 
of received investment contracts. For instance, the DC and Metroplex region experienced a 
136.7% increase in their biotech activity rising from only 49 contracts in the Q1 of 1995 - Q2 of 
2000 period, up to 116 contracts during the Q3 of 2000 – 4 of 2005 period. The Upstate New
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Table 2 
 
Aggregation of Biotech Firms in Regions 
 
N = 2890  
Region Number of Contracts 
Absolute Change 1995 to 2005 Percent Change 
(Between Groups) Q1 of 1995 -          
Q2 of 2000 
Q3 of 2000 -           
Q4 of 2005 
Difference 
(Between Groups) 
AK, HI, and PR 6 2 4 2 100.0%
Colorado 48 24 24 0 0.0%
DC and Metroplex 165 49 116 67 136.7%
LA and Orange County 91 45 46 1 2.2%
Midwest 183 67 116 49 73.1%
New England 517 208 309 101 48.6%
North Central 57 24 33 9 37.5%
Northwest 120 46 74 28 60.9%
NY Metro 168 69 99 30 43.5%
Philadelphia Metro 242 116 126 10 8.6%
Sacramento and N.Cal 10 4 6 2 50.0%
San Diego 337 127 210 83 65.4%
Silicon Valley 561 230 331 101 43.9%
South Central 13 4 9 5 125.0%
Southeast 219 88 131 43 48.9%
Southwest 56 17 39 22 129.4%
Texas 86 43 43 0 0.0%
Upstate NY 11 2 9 7 350.0%
Total 2890 1165 1725 560 48.1%
 
Note. This table displays the count of investments contracts by regions defined by PricewaterhouseCoopers’ Money Tree Report. The number of contracts 
column shows the total amount of contract in those regions from 1995 - 2005. The absolute change 1995 to 2005 column explains the total count of investment 
contracts for the first 22 quarters (Quarter 1 of 1995 – Quarter 2 of 2000)  in comparison to the last 22 quarters (Quarter 3 of 2000 – Quarter 4 of 2005) of this 
study and the difference between these two periods. The percent change (between groups) column explains the percentage growth of biotech investment contracts 
between these two periods.
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York region experienced a 350% gain in biotech investment activity. From the period Q1 of 
1995 - Q2 of 2000, Upstate New York only received two investment contracts, but that number 
grew to nine contracts during the Q3 of 2000 - Q4 of 2005 period. A couple of regions in the 
research received no (zero) increase in biotech activity from Q1 of 1995 - Q2 of 2000 to Q3 of 
2000 - Q4 of 2005. These regions include Colorado and Texas, which received the same amount 
of funding contracts in both periods. Overall, there were 1,165 investment contracts during the 
first period. This number rose to 1,725 investment contract by the second period of this research, 
resulting in the total difference of 560 contracts, or a 48.1% increase in biotech activity across 
the United States. 
Table 3 displays the differences between local and non-local investments. Local and non-
local investment counts and capital means are compared by stage of development, financial 
sequence, and funding location. Stage of development has been divided into six groups. The six 
stages of development include Start-Up and Seed, Early, Early and Expansion, Expansion, 
Expansion and Later, and Later. The Early and Expansion and Expansion and Later stages were 
added to the initial four stages used by the Money Tree Report because a handful of biotech 
companies listed two stages. Within these six stages, biotech companies received a greater 
amount of capital from their local investors in all stages except in the Start-Up and Seed stage. In 
the Start-Up and Seed stage, biotech companies received an average of $400,000 more from their 
non-local investors. The table also shows that biotech companies receive a greater amount of 
capital as they advance in their stages of development. In other words, companies in the Later 
stage of development receive the greatest average amount of capital.  
According to the biotech database, biotech companies have a financial sequence of 1 to 
18. Considering the majority of the biotech companies in this study have a financial sequence of
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Table 3 
 
Single Statistics related to the Amount of Dollar Value 
N = 2890 
  Rank 
Non-local 
Investors
Local 
Investors Overall 
Local Mean Capital 
($million)
Non-local Mean Capital 
($million)
Stage of 
Development 
Start-Up and Seed (1) 68 352 420 2.360 2.798
Early (2) 156 749 905 6.918 5.370
Early and Expansion 0 6 6 18.804 0
Expansion (3) 185 904 1089 13.439 8.165
Expansion and Later 0 5 5 39.897 0
Later (4) 68 397 465 16.655 10.978
Financial 
Sequence 
1 159 718 877 6.089 5.220
2 113 536 649 9.201 7.747
3 72 426 498 13.599 7.366
4 to 6 85 574 659 14.566 8.942
7 to 9 33 127 160 8.657 6.202
10 or more 15 32 47 7.468 3.933
Funding International 55 180 235 7.778 6.770
Domestic 422 2233 2655 15.363 9.996
 
Note. This table presents summary statistics comparing the count of contracts and mean capital for the Local Investors and Non-local Investors variables. The 
table displays both a count of contracts and means capital for several of the research variables (stage of development, financial sequence, and origin of funding). 
These variables are broken down (six stages of development, six levels of financial sequence, and two funding sources) to view the distribution of contracts and 
capital. According to the results of the table, Local Investors provide biotechnology companies with a greater average amount of investment contracts and mean 
capital than Non-local Investors in every category, with the exception of the first Stage of Development (Start-Up/Seed stage).
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1 to 3, it makes sense to combine some of the financial sequences together. In Table 3, there are 
six groups of financial sequences. The six financial sequences include 1, 2, 3, 4-6, 7-9, and 10 or 
more. According to the table, biotech companies with a financial sequence between 4 and 6 have 
the largest average mean of capital (local mean of $14,556,200 and non-local mean of 
$8,941,900). Financial sequence has a pyramid effect on capital investments. In other words, the 
average mean capital rises as the financial sequence rises, until it finally peaks at the 4-6 
sequence group. As the financial sequence rises above the 4-6 group, the average mean capital 
decreases. 
Table 4 provides information about biotech firms aggregated by U.S. regions. Similar to 
Table 2, Table 4 displays biotech information in the 18 geographic regions used by The Money 
Tree Report. The table lists the overall capital from 1995 to 2005. The table also displays the 
capital investments located in each region for the two periods in this research, Q1 of 1995 - Q2 
of 2000 and Q3 of 2000 - Q4 of 2005, and the difference in change between them. The overall 
results of the biotech database show that $28,370,799,150 (over $28 billion) was invested from 
1995 to 2005. Also, there was a 151.8% overall increase in capital growth from the first period 
($8,065,013,000) to the second period ($20,305,786,200). For the 11-year period, the Silicon 
Valley region received $7,149,583,488 and the New England region received $5,229,732,888 in 
investment capital. Combined, these two regions received over $12 billion in capital, nearly 50% 
of the total capital invested during this study. In 1995, the Alaska, Hawaii, and Puerto Rico 
region, Sacramento and North California region, and Upstate New York region received zero 
($0) capital investments. These regions, combined with South Central, represent the four least 
amounts of capital invested regions in the United States. These regions received a
46 
 
Table 4 
 
Aggregation of Money in Regions 
 
N = 2890  
Region 
Total Capital 
(Millions of 
Dollars) 
Change 1995 to 2005 (absolute) 
Percent Change 
(Between Groups) Q1 of 1995 -       
Q2 of 2000 
Q3 of 2000 -        
Q4 of 2005 
Difference 
(Between Groups) 
AK, HI, and PR 11.700 1.800 9.900 8.100 450.0%
Colorado 631.243 198.921 432.322 233.401 117.3%
DC and Metroplex 1175.593 290.894 884.699 593.805 204.1%
LA and Orange County 645.193 262.893 382.300 119.406 45.4%
Midwest 1072.278 400.414 671.864 271.450 67.8%
New England 5229.733 1390.117 3839.616 2449.500 176.2%
North Central 318.146 109.311 208.835 99.524 91.0%
Northwest 1167.243 387.537 779.707 392.170 101.2%
NY Metro 2584.365 484.467 2099.898 1615.431 333.4%
Philadelphia Metro 2112.731 696.421 1416.310 719.889 103.4%
Sacramento and N.Cal 90.900 27.200 63.700 36.500 134.2%
San Diego 3670.814 914.966 2755.848 1840.882 201.2%
Silicon Valley 7146.583 2151.644 4994.940 2843.296 132.1%
South Central 69.620 10.840 58.780 47.940 442.3%
Southeast 1619.684 437.658 1182.026 744.369 170.1%
Southwest 256.263 72.136 184.127 111.991 155.3%
Texas 541.397 226.584 314.813 88.229 38.9%
Upstate NY 27.310 1.210 26.100 24.890 2057.0%
Total 28370.799 8065.013 20305.786 12240.773 151.8%
Note. This table displays the total amount of capital venture capitalists invests by region. The Total Capital column displays the total amount of money in those 
regions from 1995 - 2005. The absolute change 1995 to 2005 column explains the total amount of capital invested for the first 22 quarters (Quarter 1 of 1995 – 
Quarter 2 of 2000) in comparison to the last 22 quarters (Quarter 3 of 2000 – Quarter 4 of 2005) of this study and the difference between these two periods. The 
percent change (between groups) column shows the percentage growth of investment capital between these two periods. 
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total of $199,530,603 over the 11-year period, less than 1% of the total overall capital 
investments.  
 Several regions experience a significant change from the first time period (first quarter of 
1995 to the second quarter of 2000) to the second time period (third quarter of 2000 to the fourth 
quarter of 2005). All regions during these periods in the United States saw a positive growth in 
their capital investments. Most notably, the Upstate New York region experienced an increase of 
2,057% in its venture capital investments, from only receiving $1,210,000 during the first period 
and over $26 million during the second period. The Alaska, Hawaii, and Puerto Rico region 
received $1,800,000 during the Q1 of 1995 – Q2 of 2000 period and nearly $10 million in the Q3 
of 2000 – Q4 of 2005, thus experiencing an increase of 450% in their capital investments. The 
Texas region experienced the smallest percentage growth in its venture capitalist investments. 
During the first period, the Texas region received $226,584,300 from venture capitalist. This 
number grew to $314,813,100 during the second resulting in an increase of only 38.9%. This 
result corresponds to Table 2, which showed the Texas region received a zero percent (0%) 
growth in its venture capital investment contracts.   
 A regression analysis was performed to see the effect independent variables have on the 
amount of capital a biotech company receives. Due to the heavy skewness of the dependent 
variable, a log transformation was performed to better fit the dependent variable into a normal 
distribution. According to the regression table (Table 5), the effects on the amount of capital a 
biotech company receives are statistically significant at the 5 % level for all independent 
variables, with the exception for the Local Investor variable.
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Table 5 
 
Regression Model 
 
N = 2890 
Analysis of Variance 
Source                   DF        
Sum of 
Squares         
Mean 
Square    f-value p-value 
Model                     8 1595.44574 199.43072 98.23 <.0001
Error                  2881 5848.96284 2.03018     
Corrected Total 2889 7444.40858       
 
Root MSE 1.42485
Dependent Mean 1.40034
Coefficient Variable 101.75007
R-Square     0.2143
Adjusted R-Sq 0.2121
 
Parameter Estimates 
Independent Variable DF 
Parameter 
Estimate         
Standard 
Error    t Value Pr > |t| 
Financial Sequence 1 -0.10199 0.01396 -7.31 <.0001 
Stage of Development 1 0.79007 0.03362 23.5 <.0001 
Minimum Distance 1 -0.0039 0.0011 -3.55 0.0004 
Local Investors 1 -0.1005 0.11877 -0.85 0.3976* 
International Investors (dummy) 1 0.44781 0.09797 4.57 <.0001 
Boom (dummy) 1 0.32803 0.06874 4.77 <.0001 
New England (dummy) 1 0.29233 0.07436 3.93 <.0001 
California (dummy) 1 0.42236 0.05967 7.08 <.0001 
y - Intercept (dummy) 1 -0.36574 0.1495 -2.45 0.0145 
 
Note. These tables present descriptive statistics of the regression model.  The Analysis of Variance table explains the 
significance independent variables have on the dependent variable. According to the f-value of 98.23 and the p-
value of <.0001 explains that the independent variables do significantly influence the amount of capital a biotech 
company receives from its investors. The Parameter Estimates table displays the independent variables (Financial 
Sequence, Stage of Development, Minimum Distance, Local Investors, International Investors, Boom, New 
England, and California) relationship and influence on the dependent variable (Capital).  * Indicates that the Local 
Investor independent variable does not have a significant effect on the dependent variable because its p-value is 
greater than .05. 
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 For instance, the Financial Sequence variable has a negative relationship with the 
dependent variable. This means as the financial sequence of biotech companies’ increase, the 
less total capital these biotech companies receive. This makes sense considering the results of 
Tian (2008) who found that local companies receive fewer rounds of capital but more overall 
capital than those firms receiving more rounds of finance. Also, the majority of the biotech 
companies in this study have a financial sequence of three or less and this influences the 
Financial Sequence variable. 
 The Stage of Development variable has a positive relationship with the dependent variable. 
In other words, as a biotech company moves to higher stages, the greater total amount of capital 
it receives from its investors. This makes sense because venture capitalists are more likely to 
invest greater capital if a biotech company is within its production phase or already profitable. 
Venture capitalists are also attracted to biotech companies in their later stages because they have 
a greater chance in reaching public (IPO). When a biotech company becomes public, venture 
capitalists can expect a significantly large payout in comparison to their invested capital.  
 Minimum distance has a negative relationship with the dependent variable. As the distance 
between venture capital firm and biotechnology company increases, the less total capital those 
biotechnology companies receive from their investors. Geographic proximity is extremely 
significant when it comes to the amount of capital a venture capitalist company will invest. Thus, 
venture capitalists are more willing to invest greater amounts of capital if the biotech company is 
close enough to effectively monitor. Aside from monitoring, being in close proximity also allows 
the investor to inspect, assist, speak with suppliers and workers, and regulate decisions based on 
the success and direction of the biotech company, while significantly reducing the costs of 
transportation, lodging, etc. 
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 The Local Investors variable has a negative association with the amount of capital a 
biotechnology company receives. In other words, the closer the distance between a biotech 
company and its venture capital investors, the smaller the quantity of capital the biotech 
companies receive. The Local Investor variable was ignored considering its p-value (Local 
Investor p-value = .3976) is greater than .05. Given the data used in this analysis the effect of the 
Local Investor variable on the amount of capital a firm receives is not statistically significant. 
 The other variables (International Investors, Boom, New England Region, and California 
Region) were used as dummy variables during this regression model. These dummy variables 
were used to detect the absence or presence of some categorical effect that may influence the 
outcome. International Investors dummy variable characterizes those biotech companies that 
receive some type of funding from foreign investors. International Investors has a positive 
relationship with the dependent variable, meaning biotech companies that receive foreign 
investments receive a greater amount of capital on average. The Boom dummy variable 
represents investments made during the internet bubble from 1999 to 2000. The Boom variable 
has a positive association with the dependent variable, meaning biotech companies received a 
greater amount of venture capital investments during this period.  
 The New England region dummy corresponds to the venture capital contracts completed 
within the New England area. New England region has a positive association with the dependent 
variable, meaning those biotech companies located within the New England region receive more 
capital on average than those companies outside of the New England region. The same is true for 
the California dummy variable. California has a positive relationship with the dependent 
variable, so those biotech companies located within the California region receive more capital on 
average than those located outside the region. On average, biotech companies located within the 
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California region receive more capital than those located within the New England region. As a 
result, the dummy variables have responded as expected. 
 The significance of the  regression table results help provide a better 
understanding on how variables influence the amount of capital a biotech company receives from 
its venture capital investors. The first research hypothesis states, the closer the spatial distance 
between venture capital investors and biotechnology companies, the more capital biotechnology 
companies receive from those venture capital investors. The result of the regression table 
supports this hypothesis. The Minimum Distance variable supported this hypothesis because it 
had a negative relationship with the amount of capital a biotech company receives. In other 
words, the farther a biotech company is from its investor, the less amount of capital those 
companies receive. The second research hypothesis states, biotech companies in later stages of 
development receive more capital from their venture capital investors. The findings show that the 
Stage of Development variable supports this hypothesis because of its positive relationship with 
the amount of capital a biotech company receives. In other words, companies in a higher stage of 
development receive more capital from its investors. The third research hypothesis states, biotech 
companies with a greater number of financial sequences receive more capital from their venture 
capital investors. The regression table shows that the Financial Sequence has a negative 
relationship with the amount of capital a biotech company receives. This means, the more 
financial sequences a biotech company receives, the less amount of capital they receive. This 
result opposes the researchers initial thought and results in the rejection of the third research 
hypothesis.  
In accordance with the regression model results, those biotech companies that receive the 
greatest amount of capital from their investors can be expected to have: 1) a great number of 
52 
 
investors; 2) are in their later stages of development; 3) receive few financial sequences; and, 4) 
are located in close proximity to their investors. 
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CHAPTER 5 
CONCLUSION 
 Due to the high-risk nature of the biotechnology industry, biotech companies have relied 
on venture capital firms to fund their potentially high-profitable projects. The greater amount of 
capital a biotechnology company receives can significantly increase its chances of success. Thus, 
the purpose of this research was to provide insight on the spatial relationship between the 
locations of biotechnology companies and the venture capitalist firms that provide them funding. 
This was done by using venture capitalists to biotech investment data gathered through the 
Money Tree Report website. Investment records from 1995 to 2005 where compiled into a large 
database containing a total of 2,890 entries. Geographic Information Systems (GIS) software was 
used to display the locations of these biotechnology companies and their venture capital 
investors. GIS was also used to create several maps as visual aids. Statistical Analysis Software 
(SAS) was used to calculate the distance between a biotechnology company and its closest 
investor using the Great Circle Routes formula and performs some statistic tables include a 
regression model. The regression model provided significant results and findings for this 
research. 
 The results show that a biotech company’s variables (financial sequence, stage of 
development, distance form investor, etc.) influence the average amount of capital a biotech 
company receives from its investors. The results suggest that biotechnology companies receive 
more capital from their venture capital investors if they are located in close proximity. This 
finding fails to reject the first research hypothesis of this research and relates to the findings of 
Tian (2008), Powell, et al. (2002), Coval and Moskowitz (2001), and Lerner (1995), who have 
all mentioned the importance of proximity in accordance to investments and overall success of 
54 
 
the company. The results also show that biotech companies in higher stages of development 
receive more capital on average from its investors. This finding fail to reject the second research 
hypothesis of this research and corresponds to the findings Sorenson and Stuart (2001), that 
biotech companies in their later stages of development receive more capital based on their 
production, success, and popularity. The results also suggest that the more financial sequences a 
biotech company receives, the less amount of capital it receives from its investors. Although this 
finding rejects the third research hypothesis of this research, it is associated with the findings of 
Tian (2008), that local firms receive fewer financial sequences, more capital, and outperform 
biotech companies located further away. 
The results of the regression table indicate that other variables have a significant 
influence on the amount of capital a biotech company receives from its investors. These other 
variables are not mentioned or related to the hypotheses of this research and include the biotech 
company’s location in either the San Francisco Bay Area or Boston Metropolitan Area clusters, 
receiving an investment during the Boom period (1999-2000), or receiving capital from foreign 
investors. Each of these variables has a positive relationship on the amount of capital a biotech 
company receives. In other words, these variables increase the average amount of capital a 
biotech company receives from its venture capital investors. 
This researcher sought to explain the unique relationship between venture capital firm 
and the biotechnology companies that provide investments. Although few publications are 
directly related to this research, the findings of this research correlates with the findings similar 
publications. 
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 APPENDIXES 
APPENDIX A 
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Figure 3: displays the both domestic and foreign venture capitalists that invested capital into United States biotechnology industry from 
1995-2005. 
 APPENDIX B 
Figure 4: Displays the locations of biotechnology and venture capital firms within the San Francisco Bay Area. Maps 
are placed side-by-side to show their relationship and prevent overlapping. 
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APPENDIX C 
 
Figure 5: Displays the locations of biotechnology and venture capital firms within the San Francisco Bay Area. 
Maps are placed side-by-side to show their relationship and prevent overlapping. 
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 APPENDIX D 
Figure 6: Displays the locations of all the biotechnology companies that receive venture capital funding from the first 
quarter of 1995 to the second quarter of 2000. 
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 APPENDIX E 
Figure 7: Displays the locations of all the biotechnology companies that receive venture capital funding from the 
third quarter of 2000 to the fourth quarter of 2005. 
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 APPENDIX F
Figure 8: Displays the percentage growth of biotechnology companies by state from the Q1/1995-Q2/2000 (first twenty-
two quarters) to Q3/2000- Q/2004 (second twenty-two quarters) 
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 APPENDIX G 
Figure 9: Displays the locations of biotechnology companies that receive a minimum of $10 million in investments 
from venture capitalists 
65 
 
io  
APPENDIX H
Figure 10: Displays the locations of biotechnology companies that receive a minimum of $25 million in investments 
from venture capitalists 
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 APPENDIX I 
Figure 11: Displays the locations of biotechnology companies that receive a minimum of $50 million in investments 
from venture capitalists 
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